- CDC
- Heart Failure
- Cardiovascular Clinical Consult
- Adult Immunization
- Hepatic Disease
- Rare Disorders
- Pediatric Immunization
- Implementing The Topcon Ocular Telehealth Platform
- Weight Management
- Monkeypox
- Guidelines
- Men's Health
- Psychiatry
- Allergy
- Nutrition
- Women's Health
- Cardiology
- Substance Use
- Pediatrics
- Kidney Disease
- Genetics
- Complimentary & Alternative Medicine
- Dermatology
- Endocrinology
- Oral Medicine
- Otorhinolaryngologic Diseases
- Pain
- Gastrointestinal Disorders
- Geriatrics
- Infection
- Musculoskeletal Disorders
- Obesity
- Rheumatology
- Technology
- Cancer
- Nephrology
- Anemia
- Neurology
- Pulmonology
FDA Okays First DDP-4 Inhibitor for Type 2 Diabetes
ROCKVILLE, Md. -- The FDA approved Januvia (sitagliptin) today, the first dipetidyl peptidase-4 (DDP-4) inhibitor, an oral agent for type 2 diabetes as monotherapy or in combination with Glucophage (metformin) or a PPAR agonist.
ROCKVILLE, Md., Oct. 17 -- The FDA approved Januvia (sitagliptin) today, the first dipetidyl peptidase-4 (DDP-4) inhibitor, an oral agent for type 2 diabetes.
The agent was approved as monotherapy or in combination with Glucophage (metformin) or a peroxisome proliferator-activated receptor (PPAR) agonist, such as Actos (pioglitazone).or Avandia (rosiglitazone).
The price of once-daily Januvia, marketed by Merck, was not disclosed by press reports put it in the range of a pill. Another DDP-4 called Glavus, made by Novartis, is awaiting FDA approval.
Januvia was evaluated in a total of 2,719 patients with type 2 diabetes, in studies lasting from 12 weeks to more than a year, according to the FDA. These studies demonstrated improved blood sugar control when Januvia was used alone or in patients not satisfactorily managed with metformin or a PPAR agonist.
The most common side effects in clinical studies were upper respiratory tract infection, sore throat, and diarrhea.
